FDA rolls out inaugural pathway for tailor-made rare-disease drugs
The FDA unveiled a new plausible mechanism pathway to approve medicines crafted for patients’ individual mutations, moving the idea from preview into formal policy and potentially enabling gene-editing–based and other targeted therapies for rare diseases.